- The shares of cancer test maker Guardant Health ( NASDAQ: GH ) recovered from two consecutive days of losses on Tuesday after the company announced it received Medicare coverage for the Guardant Reveal molecular residual disease (MRD) test.
- The decision of Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), means Guardant Reveal is covered in the U.S. for certain Medicare patients with stage II or III colorectal cancer (CRC).
- Designed to detect circulating tumor DNA in the blood after surgery, Guardant Reveal can detect residual or recurring disease helping patients to benefit from adjuvant therapy.
- The test is the first blood-based liquid biopsy test available for patients with CRC for MRD testing.
- Read: Seeking Alpha contributor BioSci Capital Partners reiterated his Buy rating on Guardant ( GH ) in July, noting, among others, favorable industry trends for precision medicine diagnostics.
For further details see:
Guardant Health rebounds as liquid biopsy test granted Medicare coverage